The DOI matches its Crossref record; 59 of the 62 references it cites were found in a registry or an index; 14 of the 23 sources its claims cite were checked for support.
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
Open accessAbstract
Thirty-nine articles were included in the review showing a total number of 33,354 individuals. Nausea, vomiting, diarrhea, and constipation were the most common gastrointestinal adverse effects. All evaluated GLP-1 RAs led to a significant increase in nausea risk, with orforglipron showing the highest risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. Additionally, liraglutide, orforglipron, semaglutide, and tirzepatide were associated with increased vomiting risk, while cagrilinitide and exenatide showed no significant increase. Exenatide, cagrilinitide, orforglipron were not associated with diarrhea risk. Finally, semaglutide and liraglutide were associated to increased constipation risk, while cagrilinitide and exenatide showed no significant increase.
Overview
CoChat Summary
## TL;DR
This systematic review and dose-response network meta-analysis included 39 articles and 33,354 non-diabetic adults with overweight or obesity to compare gastrointestinal adverse events across GLP-1 receptor agonists and related agents. All evaluated drugs increased nausea risk, while higher doses were associated with more nausea, vomiting, diarrhea, constipation, and decreased appetite.
## Key findings
- The review included 39 articles and 33,354 individuals; the most common gastrointestinal adverse effects were nausea, vomiting, diarrhea, and constipation.
- All evaluated GLP-1 RAs significantly increased nausea risk; the highest risk was with orforglipron (RR 4.7748, 95% CI 2.0161–11.3085), followed by liraglutide, semaglutide, tirzepatide, exenatide, and cagrilinitide.
- Vomiting risk increased with liraglutide (RR 3.8722), orforglipron (RR 3.8722), semaglutide (RR 4.2108), and tirzepatide (RR 13.2265); cagrilinitide and exenatide were not significantly increased.
- Diarrhea was significantly increased with semaglutide (RR 1.7714), liraglutide (RR 1.8231), and tirzepatide (RR 3.3537), while exenatide, cagrilinitide, and orforglipron were not.
- In dose-response analyses, higher doses of GLP-1 RAs were associated with increased risks of nausea, vomiting, diarrhea, constipation, and decreased appetite, with many outcomes rising quickly at lower doses then plateauing.
## Methods
- Design: Systematic review and dose-response network meta-analysis, conducted according to PRISMA 2020.
- Data/sample: Searches of PubMed and EMBASE from inception to December 20, 2023; 39 interventional studies/RCTs in non-diabetic adults with overweight or obesity.
- Analysis: Random-effects network meta-analysis using restricted maximum likelihood, with comparisons reported as RRs with 95% CIs; heterogeneity assessed with Q-test and I², and risk of bias evaluated with the Cochrane Collaboration tool.
## Limitations
- The paper states there was significant heterogeneity in study design, populations, dose regimens, and follow-up duration, and that some trials had high risk of bias; these factors could affect reliability.
- Some adverse events were reported in few trials (e.g., viral gastroenteritis, hard feces, infrequent bowel movements), limiting robust analyses.
- The authors state they could not do duration-based subgroup analyses because of missing stratified time-point data, and they could not compare adult vs. elderly or pediatric/adolescent groups because included studies enrolled adults only.
- Evident from the text: most studies came from a limited set of countries (U.S., Denmark, China, Slovenia), so generalizability may be limited; reporting/classification differences across studies may also have introduced inconsistency.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
8 Valid · 4 Not valid · 6 Not checked · 123 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, abdominal symptoms are often related to acute pancreatis, but extensive cardiovascular outcome trials have not demonstrated an elevated risk of pancreatitis associated with GLP-1RAs [60].”
§ Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis > Discussion
What the sources say
- Supportedcites [60] Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. source
The Gastrointestinal and other adverse events section reports that large randomized cardiovascular outcome studies carefully adjudicated suspected pancreatitis and uniformly found hazard ratios not significantly different from 1.0. This supports the claim that those trials did not demonstrate an elevated pancreatitis risk with GLP-1 RAs. (LLM, conf=0.93)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Likewise, compared to placebo, several GLP-1 RAs including orforglipron, tirzepatide, semaglutide, liraglutide, and exenatide were associated with a significantly increased risk of vomiting [53].”
§ Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis > Discussion
What the sources say
- Supportedcites [53] Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. source
The Results > Adverse events passage explicitly lists orforglipron, tirzepatide, semaglutide, liraglutide, and exenatide among ten GLP-1RAs associated with a significantly higher risk of vomiting than placebo. The analysis concerns adults with type 2 diabetes. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“semaglutide (RR 1.4005 [95% CI 1.1100, 1.7671; p-value 0.0045])”
§ Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis > Results > Flatulence
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“exenatide (RR 6.5609 [95% CI 0.8253, 52.1544; p-value 0.0753])”
§ Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis > Results > Abdominal distention
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“tirzepatide (RR 1.3566 [95% CI 0.2354, 7.8184; p-value 0.7329]), liraglutide (RR 1.7470 [95% CI 0.5471, 5.5783; p-value 0.3462]), and semaglutide (RR 1.9181 [95% CI 0.2354, 7.8184; p-value 0.7329])”
§ Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis > Results > Cholelithiasis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
88 more claims
Create a free account to see all 141 claims and to verify the 3 references still open.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 30
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Yet the dominant physiological driver of discontinuation and non-persistence remains gastrointestinal (GI) intolerance, an intrinsic consequence of GLP-1 receptor activation in the gut and brainstem [23,24].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent systematic review of 39 randomized controlled trials of GLP-1RAs showed a class effect of increased risks of nausea, vomiting, diarrhea and constipation compared with placebo (15) in individuals without diabetes.”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GI adverse events remain the most frequently cited medical reason for discontinuation across both clinical trial and real-world settings [24,53].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“tirzepatide RR 2.90 (95% CI 2–4.19)”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“semaglutide relative risk (RR) 2.95 (95% CI 2.61–3.32)”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [15]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“Trials with strati fi ed data by age, disease status, and treatment duration will be instrumental in re fi ning patient-centered prescribing practices.”
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Research works printed but not linked: 1
- Zhuo-yue G, Tian-sheng W, Man-ling M, Suo-di Z. A meta-analysis of GI adverse events of GLP-1 receptor agonists and DPP-4 inhibitors. Chin Pharm J. 2014;49:935–940.
Cited by
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“In the systematic review of clinical trials mentioned above, tirzepatide conferred the greatest risk of vomiting, RR 13 (15).”
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Sievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 56
“The most common adverse effects (AEs) associated with GBTs are GI, mainly nausea, vomiting, diarrhoea and constipation [22,23].”
Chao, A. M., Gilden, A. H., & Wadden, T. A. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004871 · Cited by 16
GLP-1 Receptor Agonists in Heart Failure
Rahmani, A. R., Dhaliwal, S., Pastena, P., Kazakov, E., Jayaseelan, K., & Kalogeropoulos, A. P. (2025) · Biomolecules · doi:10.3390/biom15101403 · Cited by 19
“A recent meta-analysis in non-diabetic patients with overweight or obesity confirmed higher risks of nausea, vomiting, diarrhea, and constipation, particularly with semaglutide, liraglutide, and tirzepatide [36].”
Metadata
- Authors
- Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L.
- Affiliations
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Magna Graecia University (IT)
- Corresponding author
- Leucuta, Daniel-Corneliu
- ORCID
- Venue
- International Journal of Obesity
- Published
- 2025-08-13
- Volume
- 49
- Issue
- 10
- Pages
- 1946-1957
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- PMC
- PMC12532569
- OpenAlex
- W4413117488
- Cited by
- 99
- References
- 62
- Citations by year
- 2026: 90 · 2025: 9
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- International Journal of Obesity (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, vomiting, diarrhea, constipation, non-diabetic patients, obesity, overweight, weight loss, orforglipron, exenatide, tirzepatide, semaglutide, liraglutide, dose-response relationship
- MeSH terms
- Network Meta-Analysis as Topic, Glucagon-Like Peptide-1 Receptor Agonists, Gastrointestinal Diseases, Humans, Obesity, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1038/s41366-025-01859-6
- The paper
- Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025). Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. International Journal of Obesity. https://doi.org/10.1038/s41366-025-01859-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.